Novartis Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
76,057
- Stock Symbol
-
NOVN
- Investments
-
152
- Share Price
-
$115.83
- (As of Wednesday Closing)
Novartis General Information
Description
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Contact Information
Website
www.novartis.comCorporate Office
- LICHTSTRASSE 35
- 4056 Basel
- Switzerland
Corporate Office
- LICHTSTRASSE 35
- 4056 Basel
- Switzerland
Novartis Timeline
Novartis Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $115.83 | $116.05 | $91.61 - $121.35 | $235B | 2.02B | 2.95M | $7.86 |
Novartis Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 235,981,136 | 219,368,583 | 204,257,863 | 222,803,525 |
| Revenue | 48,860,000 | 46,660,000 | 43,461,000 | 43,974,000 |
| EBITDA | 18,353,000 | 14,486,000 | 13,045,000 | 30,844,000 |
| Net Income | 16,175,000 | 14,850,000 | 6,955,000 | 24,021,000 |
| Total Assets | 97,505,000 | 99,945,000 | 117,453,000 | 131,795,000 |
| Total Debt | 28,987,000 | 26,348,000 | 27,909,000 | 31,025,000 |
Novartis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Novartis Comparisons
Industry
Financing
Details
000000
000
Novartis Competitors (40)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gilead Sciences | Formerly VC-backed | Foster City, CA | 00000 | 000.00 | 0000 | |
| GSK | Corporation | Middlesex, United Kingdom | 00000 | 00.000 | 000000000 | 00.000 |
| Merck & Co. | Corporation | Rahway, NJ | 00000 | 0000 | 000000000 - | 0000 |
| AstraZeneca | Formerly PE-Backed | Cambridge, United Kingdom | 00000 | 000.00 | 000000000 00 | 000.00 |
| AbbVie | Corporation | North Chicago, IL | 00000 | 00.000 | 000000000 - | 00.000 |
Novartis Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Novartis Patents
Novartis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| DE-202024000928-U1 | Omalizumab injection | Active | 10-May-2024 | 000000000 | 0 |
| GB-202408006-D0 | New uses of omalizumab | Pending | 28-Jul-2023 | 00000000000 | |
| DE-202024001265-U1 | Syringe prepared for practical use | Active | 28-Jul-2023 | 00000000000 | 0 |
| US-12030959-B1 | Anti-ige antibody therapy for multiple food allergies | Active | 05-Jul-2023 | 000000000 | 00 |
| US-20240245694-A1 | Tricyclic compounds and their uses | Pending | 04-Apr-2023 | A61K31/5377 |
Novartis Executive Team (141)
| Name | Title | Board Seat |
|---|---|---|
| Vasant Narasimhan MD | Chief Executive Officer & Member of the Executive Committee | |
| Heinrich Moisa | President & Managing Director, Germany | |
| Shreeram Aradhye MD | President, Global Drug Development, Member of the Executive Committee & Chief Medical Officer | |
| Matt Zeller | Country President, Hungary | |
| Andrea Marazzi | Country President, Novartis Pharmaceuticals Canada Inc. |
Novartis Board Members (19)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000 00 000 0000000 | Self | Board Member, Member of Audit and Compliance Committee & Member of Risk Committee | 000 0000 |
| 000000000 000000 | Self | Board Member, Member of Audit and Compliance Committee, Member of Compensation Committee & Member of Governance, Sustainability and Nomination Committee | 000 0000 |
| 0000000 0000000 00 | Self | Board Member, Member of Governance, Sustainability and Nomination Committee & Member of Science & Technology Committee | 000 0000 |
| 000000000 0000000 | Self | Board Member, Audit Committee Financial Expert, Chairman of Audit and Compliance Committee & Member of Risk Committee | 000 0000 |
| 00000 000 000000 | Self | Board Member, Member of Audit and Compliance Committee & Member of Science & Technology Committee | 000 0000 |
Novartis Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Novartis Investments & Acquisitions (152)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ONL Therapeutics | 16-Sep-2024 | 00000 0000 | 0000 | Drug Discovery | |
| Borealis Biosciences | 22-Aug-2024 | 00000 0000 | 00000 | Discovery Tools (Healthcare) | 00000 000 |
| Dren Bio | 24-Jul-2024 | 00000 0000 | 0000 | Biotechnology | 00000 000 |
| MorphoSys | 20-Jun-2024 | 0000000000 | 0000 | Biotechnology | 00000000 |
| Mariana Oncology | 02-May-2024 | Merger/Acquisition | 00.000 | Drug Discovery |
Novartis Subsidiaries (22)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| SanReno Therapeutics | Biotechnology | Shanghai, China | 2021 |
| Vedere Bio II | Drug Discovery | Cambridge, MA | 0000 |
| Chinook Therapeutics | Drug Discovery | Seattle, WA | 0000 |
| Gyroscope | Drug Discovery | London, United Kingdom | 0000 |
| Navigate BioPharma | Biotechnology | Carlsbad, CA | 0000 |
Novartis ESG
Risk Overview
Risk Rating
Updated July, 30, 2024
13.6 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
0. of 446
Rank
Percentile
Novartis Exits (51)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| SomaLogic | 31-Aug-2021 | 0000 | 00000 | Completed |
|
| TScan Therapeutics | 15-Jan-2021 | 00000 00000 | 00000 | Completed |
|
| Aspen RxHealth | 18-Dec-2020 | 00000 00000 | 0000 | Completed |
|
| SomaLogic | 25-Nov-2020 | 00 000000000 | 00000 | Completed |
|
| Paprika Care | 19-Oct-2020 | Seed Round | Completed |
|
Novartis FAQs
-
When was Novartis founded?
Novartis was founded in 1996.
-
Who is the CEO of Novartis?
Vasant Narasimhan MD is the CEO of Novartis.
-
Where is Novartis headquartered?
Novartis is headquartered in Basel, Switzerland.
-
What is the size of Novartis?
Novartis has 76,057 total employees.
-
What industry is Novartis in?
Novartis’s primary industry is Pharmaceuticals.
-
Is Novartis a private or public company?
Novartis is a Public company.
-
What is Novartis’s stock symbol?
The ticker symbol for Novartis is NOVN.
-
What is the current stock price of Novartis?
As of 18-Sep-2024 the stock price of Novartis is $115.83.
-
What is the current market cap of Novartis?
The current market capitalization of Novartis is $235B.
-
What is Novartis’s current revenue?
The trailing twelve month revenue for Novartis is $48.9B.
-
Who are Novartis’s competitors?
Gilead Sciences, GSK, Merck & Co., AstraZeneca, and AbbVie are some of the 40 competitors of Novartis.
-
What is Novartis’s annual earnings per share (EPS)?
Novartis’s EPS for 12 months was $7.86.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
